Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-621 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ABBV-621 + FOLFIRI is a combination therapy consisting of the investigational biologic ABBV-621 (eftozanermin alfa), a TRAIL receptor agonist, and the established chemotherapy regimen FOLFIRI, which includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. ABBV-621 is designed to activate the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, inducing apoptosis in cancer cells. FOLFIRI disrupts cancer cell proliferation through DNA synthesis inhibition and topoisomerase I inhibition. This combination has demonstrated synergistic anti-tumor activity in preclinical models and is being studied especially for metastatic colorectal cancer and other solid tumors[1][3][5].
- Other names
- ABBV-621 and FOLFIRIABBV621 and FOLFIRIABBV 621 and FOLFIRI
02
Targets
TNFRSF10B (DR5)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on ABBV-621 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-621 + FOLFIRI.